Prognosis of severe attacks in ulcerative colitis:: effect of intensive medical treatment

被引:48
作者
Benazzato, L
D'Incà, R
Grigoletto, F
Perissinotto, E
Medici, V
Angriman, I
Sturniolo, GC
机构
[1] Univ Padua, Dept Surg & Gastroenterol Sci, I-35100 Padua, Italy
[2] Univ Padua, Dept Environm Med & Publ Hlth, Padua, Italy
关键词
azathioprine; cyclosporin; severe colitis;
D O I
10.1016/j.dld.2003.12.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Severe attacks of ulcerative colitis have a high risk of colectomy. Aims. To evaluate the effects of standard medical management and to identify the clinical and laboratory variables capable of predicting the clinical Outcome. Materials and methods. Prospective study monitoring the clinical and laboratory variables in 67 patients with severe colitis. Therapy consisted of prednisone, cyclosporin if no response, and azathioprine for maintenance. End-points were colectomy or remission. Logistic regression analysis was applied for statistical evaluation. Results. Fourteen (20%) patients required colectomy, 34 (50%) patients achieved remission with steroids, 25 (37%) Patients received cyclosporin. 19 (76%) with benefit. Increased body temperature, pulse rate, sedimentation rate and C-reactive protein levels on admission were significantly associated with colectomy. Sedimentation rate greater than 75 mm/h and body temperature exceeding 38 degreesC at admission had 4.6- and 8.8-fold increased risk of colectomy. Less than 40% reduction in the bowel movements within 5 days predicted no response to steroids. Azathioprine maintained remission in 70% of the patients. Conclusions. Elevated sedimentation rate and fever at day 1 best predict colectomy in severe colitis. Less than 40% reduction in the bowel movements at day 5 predicts no response to steroids. Cyclosporin has a high rate of success in acute attacks and azathioprine ill maintaining remission. (C) 2004 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:461 / 466
页数:6
相关论文
共 19 条
  • [1] Carbonnel F, 2000, ALIMENT PHARM THERAP, V14, P273
  • [2] Caroli A, 2000, AM J GASTROENTEROL, V95, P3016, DOI 10.1111/j.1572-0241.2000.03239.x
  • [3] CHAKRAVARTY BJ, 1993, AM J GASTROENTEROL, V88, P852
  • [4] Cohen RD, 1999, AM J GASTROENTEROL, V94, P1587
  • [5] Intravenous cyclosporine in severe ulcerative colitis: Ready to stand alone?
    Cohen, RD
    [J]. GASTROENTEROLOGY, 2001, 120 (06) : 1541 - 1543
  • [6] Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis
    Domènech, E
    Garcia-Planella, E
    Bernal, I
    Rosinach, M
    Cabré, E
    Fluvià, L
    Boix, J
    Gassull, MA
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (12) : 2061 - 2065
  • [7] FernandezBanares F, 1996, AM J GASTROENTEROL, V91, P2498
  • [8] George J, 1996, AM J GASTROENTEROL, V91, P1711
  • [9] Predicting outcome and risk assessment in severe ulcerative colitis
    Ho, GT
    Mowat, C
    Goddard, C
    Fennell, J
    Shah, N
    Prescott, R
    Satsangi, J
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : A2 - A3
  • [10] Review article: The management of severe ulcerative colitis
    Hyde, GM
    Jewell, DP
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (03) : 419 - 424